{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Stereotactic+Body+Radiation+Therapy+%28SBRT%29&page=20",
    "query": {
      "intervention": "Stereotactic Body Radiation Therapy (SBRT)",
      "page": 20
    },
    "page_size": 10
  },
  "pagination": {
    "page": 20,
    "page_size": 10,
    "total_count": 600,
    "total_pages": 60,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Stereotactic+Body+Radiation+Therapy+%28SBRT%29&page=21&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Stereotactic+Body+Radiation+Therapy+%28SBRT%29&page=19&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T17:35:52.271Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03220854",
      "title": "SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Stereotactic radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "Biological: humanized anti-PD-1 monoclonal antibody",
          "type": "OTHER"
        },
        {
          "name": "Biological: humanized anti-PD-L1 monoclonal antibody",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2017-10-10",
      "completion_date": "2021-09-22",
      "has_results": true,
      "last_update_posted_date": "2022-01-10",
      "last_synced_at": "2026-10-15T17:35:52.271Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03220854"
    },
    {
      "nct_id": "NCT02710253",
      "title": "Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Metastatic Malignant Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "External Beam Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Stereotactic Body Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 214,
      "start_date": "2016-05-25",
      "completion_date": "2026-06-24",
      "has_results": false,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-10-15T17:35:52.271Z",
      "location_count": 5,
      "location_summary": "Conroe, Texas • Houston, Texas • League City, Texas + 1 more",
      "locations": [
        {
          "city": "Conroe",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "League City",
          "state": "Texas"
        },
        {
          "city": "Sugar Land",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02710253"
    },
    {
      "nct_id": "NCT07824583",
      "title": "A Study Evaluating a New Radiation Treatment Workflow (NGDS)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Lung Cancer (Diagnosis)",
        "Liver Cancer, Adult",
        "Pancreatic Cancer",
        "Thoracic Cancers",
        "Abdominal Cancer"
      ],
      "interventions": [
        {
          "name": "Next Generation Delivery System (NGDS)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Varian, a Siemens Healthineers Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2026-07-31",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-10-15T17:35:52.271Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri • Cleveland, Ohio",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07824583"
    },
    {
      "nct_id": "NCT07223541",
      "title": "Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clear Cell Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cemiplimab 350 MG Intravenous Solution",
          "type": "DRUG"
        },
        {
          "name": "Fianlimab 1600 MG Intravenous Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Oklahoma",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2026-01-15",
      "completion_date": "2031-08",
      "has_results": false,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-10-15T17:35:52.271Z",
      "location_count": 1,
      "location_summary": "Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07223541"
    },
    {
      "nct_id": "NCT03833154",
      "title": "Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "(Osimertinib cohort, single-arm, open-label separate cohort)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 724,
      "start_date": "2019-03-06",
      "completion_date": "2028-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-20",
      "last_synced_at": "2026-10-15T17:35:52.271Z",
      "location_count": 80,
      "location_summary": "Tuscaloosa, Alabama • Chandler, Arizona • Phoenix, Arizona + 72 more",
      "locations": [
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03833154"
    },
    {
      "nct_id": "NCT02031237",
      "title": "MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Brain Metastases"
      ],
      "interventions": [
        {
          "name": "Single Fraction Stereotactic Radiosurgery (SRS)",
          "type": "RADIATION"
        },
        {
          "name": "Fractionated Whole Brain Radiation Therapy (WBRT)",
          "type": "RADIATION"
        },
        {
          "name": "Fractionated Stereotactic Radiation Therapy (FSRT)",
          "type": "RADIATION"
        },
        {
          "name": "Magnetic Resonance Imaging (MRI) Assessments",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DEVICE"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2005-04",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2019-07-26",
      "last_synced_at": "2026-10-15T17:35:52.271Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02031237"
    },
    {
      "nct_id": "NCT07530172",
      "title": "Radioembolization Versus External Radiation Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Heptocellular Cancer"
      ],
      "interventions": [
        {
          "name": "Transarterial Radioembolization",
          "type": "RADIATION"
        },
        {
          "name": "Stereotactic Body Radiation Therapy (SBRT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Henry Ford Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 146,
      "start_date": "2025-12-08",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-10-15T17:35:52.271Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07530172"
    },
    {
      "nct_id": "NCT05155046",
      "title": "18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Localized Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "18F-DCFPyL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "MALE",
        "summary": "18 Years to 120 Years · Male only"
      },
      "enrollment_count": 130,
      "start_date": "2022-08-31",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-10-15T17:35:52.271Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05155046"
    },
    {
      "nct_id": "NCT07686380",
      "title": "IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Prostate Cancer",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "N-803",
          "type": "DRUG"
        },
        {
          "name": "ETBX-71 Vaccine",
          "type": "DRUG"
        },
        {
          "name": "18F-DCFPyL",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "MALE",
        "summary": "18 Years to 120 Years · Male only"
      },
      "enrollment_count": 65,
      "start_date": "2026-10-01",
      "completion_date": "2029-01-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-15T17:35:52.271Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07686380"
    },
    {
      "nct_id": "NCT02608385",
      "title": "Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Stereotactic body radiotherapy (SBRT)",
          "type": "RADIATION"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 117,
      "start_date": "2015-12",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2025-06-08",
      "last_synced_at": "2026-10-15T17:35:52.271Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02608385"
    }
  ]
}